T. Rowe Price reports 9.6M-share stake in Lazard
T. Rowe Price Associates, Inc. amended its Schedule 13G to report beneficial ownership of 9,601,861 shares of Lazard Inc common stock, representing 8.6% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
T. Rowe Price Associates, Inc. amended its Schedule 13G to report beneficial ownership of 9,601,861 shares of Lazard Inc common stock, representing 8.6% of the class. The filing lists 9,547,474 shares as sole voting power. The filing includes the statement that "beneficial ownership is expressly denied."
Insights
Large passive holding reported with an ownership denial clause.
The filing shows 9,601,861 shares and 9,547,474 sole voting power, equivalent to 8.6% of Lazard's common stock. The holder is identified as T. Rowe Price Associates, Inc.
Because the filing includes a denial of beneficial ownership, the practical control and economic exposure should be interpreted cautiously; subsequent disclosures or regulatory context may clarify intent.
Key Figures
Key Terms
Schedule 13G/A regulatory
Sole Voting Power financial
Beneficial ownership denial regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Lazard (LAZ) does T. Rowe Price report?
Does this Schedule 13G/A mean T. Rowe Price controls Lazard votes?
When was the amended Schedule 13G/A signed?
What does the filing's "beneficial ownership is expressly denied" clause mean?
AI-generated analysis. How Rhea-AI works. Not financial advice.